Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 04 April 2013 | By Louise Zornoza,
Brazil's National Health Surveillance Agency (Anvisa) has proposed the formation of an electronic tracking system for drugs that would follow a drug from the point of manufacture to its dispensation to a patient.
The proposal was outlined in a consultation announced by Anvisa on 4 April 2013.
The proposed tracking system is to be based on the two-dimensional barcode, the Datamatrix, which will be included on sales packaging as well as secondary packaging such as pill packs and hospital packs.
According to the CEO of Anvisa, Dirceu Barbano, "Companies holding registration with Anvisa will be responsible for placing on each package a Unique Drug Identifier (IUM) formed by the drug registration number for the product containing thirteen (13) digits, plus the serial number, expiration date and lot number."
The drug industry would have 180 days to comply with the new requirement and retail sales outlets would have 360 days. The comment period will be open from 10 April through 9 May 2013.